Twist Bioscience Corp (NASDAQ:TWST) COO Sells $656,920.00 in Stock

Share on StockTwits

Twist Bioscience Corp (NASDAQ:TWST) COO William Banyai sold 22,000 shares of Twist Bioscience stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $29.86, for a total transaction of $656,920.00.

William Banyai also recently made the following trade(s):

  • On Tuesday, August 27th, William Banyai sold 22,000 shares of Twist Bioscience stock. The stock was sold at an average price of $27.92, for a total transaction of $614,240.00.

TWST traded down $1.00 during trading on Thursday, reaching $28.81. 4,627 shares of the company’s stock were exchanged, compared to its average volume of 216,983. Twist Bioscience Corp has a 1 year low of $12.38 and a 1 year high of $35.95. The company has a debt-to-equity ratio of 0.03, a current ratio of 7.18 and a quick ratio of 6.96. The stock has a market capitalization of $985.56 million and a P/E ratio of -1.13. The company’s fifty day simple moving average is $29.26 and its 200-day simple moving average is $26.98.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.92) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.83) by ($0.09). Twist Bioscience had a negative return on equity of 168.45% and a negative net margin of 204.63%. The business had revenue of $13.60 million for the quarter, compared to analysts’ expectations of $12.51 million. Equities analysts forecast that Twist Bioscience Corp will post -3.8 EPS for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Elkfork Partners LLC raised its position in Twist Bioscience by 100.0% during the 2nd quarter. Elkfork Partners LLC now owns 924 shares of the company’s stock worth $27,000 after buying an additional 462 shares during the last quarter. Morgan Stanley raised its position in Twist Bioscience by 28.9% during the 2nd quarter. Morgan Stanley now owns 2,223 shares of the company’s stock worth $65,000 after buying an additional 499 shares during the last quarter. Meadow Creek Investment Management LLC raised its position in Twist Bioscience by 100.0% during the 2nd quarter. Meadow Creek Investment Management LLC now owns 1,176 shares of the company’s stock worth $34,000 after buying an additional 588 shares during the last quarter. Glen Harbor Capital Management LLC raised its position in Twist Bioscience by 100.0% during the 2nd quarter. Glen Harbor Capital Management LLC now owns 1,428 shares of the company’s stock worth $41,000 after buying an additional 714 shares during the last quarter. Finally, Tower Research Capital LLC TRC raised its position in Twist Bioscience by 536.9% during the 2nd quarter. Tower Research Capital LLC TRC now owns 1,484 shares of the company’s stock worth $43,000 after buying an additional 1,251 shares during the last quarter. 42.69% of the stock is owned by institutional investors.

A number of research firms recently commented on TWST. ValuEngine upgraded shares of Twist Bioscience from a “hold” rating to a “buy” rating in a research note on Thursday, August 1st. Evercore ISI started coverage on shares of Twist Bioscience in a research report on Friday, May 31st. They set an “outperform” rating and a $26.66 price target for the company. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Twist Bioscience presently has an average rating of “Buy” and an average target price of $26.55.

About Twist Bioscience

Twist Bioscience Corporation, a synthetic biology company, manufactures and sells synthetic DNA-based products. The company's DNA synthesis platform enables the manufacturing of synthetic DNA by writing DNA on a silicon chip. It offers synthetic DNA-based products, including synthetic genes, tools for sample preparation, antibody libraries for drug discovery and development, and DNA as a digital data storage medium.

Featured Story: Momentum Investing

Insider Buying and Selling by Quarter for Twist Bioscience (NASDAQ:TWST)

Receive News & Ratings for Twist Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Twist Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.